TY  - JOUR
AU  - Lepenies, Laura K.
AU  - Seidling, Hanna M.
AU  - Pabst, Alexander
AU  - Luppa, Melanie
AU  - Döhring, Juliane
AU  - Williamson, Martin
AU  - Frese, Thomas
AU  - Gensichen, Jochen
AU  - Hoffmann, Wolfgang
AU  - Kaduszkiewicz, Hanna
AU  - König, Hans-Helmut
AU  - Thyrian, Jochen René
AU  - Wiese, Birgitt
AU  - Riedel-Heller, Steffi G.
AU  - Czock, David
TI  - Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de
JO  - British journal of clinical pharmacology
VL  - 91
IS  - 12
SN  - 0306-5251
CY  - Oxford
PB  - Wiley-Blackwell
M1  - DZNE-2025-01305
SP  - 3489 - 3500
PY  - 2025
AB  -  Drugs with anticholinergic effects are often considered as potentially inappropriate medications, especially for older patients, and deprescribing such drugs may improve cognitive function. The aim was to investigate the effectiveness of counselling on drug risks as part of a multimodal intervention to prevent cognitive decline.The AgeWell.de study, a multi-centre, cluster-randomized controlled study, was conducted in 123 German general practices between June 2018 and January 2022. The study included a multicomponent intervention programme for patients at increased risk of dementia, delivered over a 2-year period. As part of the medication optimisation intervention, patient data and medication records were screened to identify medication risks and provide recommendations to general practitioners.In total, 808 patients with complete data were included in the present analysis (intervention group = 374, control group = 434). At baseline, 132 (16.8
KW  - Humans
KW  - Cholinergic Antagonists: adverse effects
KW  - Cholinergic Antagonists: administration & dosage
KW  - Male
KW  - Female
KW  - Dementia: prevention & control
KW  - Dementia: chemically induced
KW  - Dementia: epidemiology
KW  - Aged
KW  - Deprescriptions
KW  - Aged, 80 and over
KW  - Inappropriate Prescribing: prevention & control
KW  - Germany
KW  - Counseling: methods
KW  - General Practice
KW  - Cognitive Dysfunction: prevention & control
KW  - Cognitive Dysfunction: chemically induced
KW  - Risk Factors
KW  - anticholinergic drugs (Other)
KW  - dementia (Other)
KW  - deprescribing (Other)
KW  - lifestyle intervention (Other)
KW  - randomized controlled study (Other)
KW  - Cholinergic Antagonists (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40817636
C2  - pmc:PMC12648363
DO  - DOI:10.1002/bcp.70194
UR  - https://pub.dzne.de/record/282542
ER  -